{"id":390971,"date":"2017-02-17T00:00:00","date_gmt":"2017-02-17T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneon0001-2017-biopharma-breast-cancer-unmet-need-us-eu-advanced-metastatic-triple-negative-breast-cancer-2017\/"},"modified":"2026-05-02T23:39:24","modified_gmt":"2026-05-02T23:39:24","slug":"unneon0001-2017-biopharma-breast-cancer-unmet-need-us-eu-advanced-metastatic-triple-negative-breast-cancer-2017","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneon0001-2017-biopharma-breast-cancer-unmet-need-us-eu-advanced-metastatic-triple-negative-breast-cancer-2017\/","title":{"rendered":"Breast Cancer | Unmet Need | US\/EU: Advanced\/Metastatic Triple-Negative Breast Cancer | 2017"},"content":{"rendered":"<p>There are limited treatment options for patients with advanced\/metastatic, triple-negative breast cancer because commonly used treatments in other breast cancer segments (i.e., hormonal therapies and HER2-targeted therapies) are ineffective in this disease subset. Hence, a high unmet need exists for efficacious targeted therapies for this patient population. Several novel therapies are in development for advanced\/metastatic, triple-negative breast cancer; however, historically, it has been difficult for agents to improve outcomes for this hard-to-treat population. Our content examines key drivers of prescribing in this indication and analyses of significant commercial opportunities.<\/p>\n","protected":false},"template":"","class_list":["post-390971","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-breast-cancer","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390971","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390971\/revisions"}],"predecessor-version":[{"id":394094,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390971\/revisions\/394094"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390971"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}